X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1203) 1203
humans (1165) 1165
animals (635) 635
female (629) 629
immunology (526) 526
b7-h1 antigen - metabolism (509) 509
immunotherapy (500) 500
male (496) 496
oncology (484) 484
mice (483) 483
cancer (414) 414
expression (380) 380
b7-h1 antigen - immunology (360) 360
lymphocytes (356) 356
middle aged (356) 356
apoptosis (346) 346
pd-l1 (332) 332
pd-1 (314) 314
b7-h1 (313) 313
adult (308) 308
b7-h1 antigen - genetics (307) 307
ligands (305) 305
b7-h1 antigen (295) 295
t cells (293) 293
article (272) 272
pd-l1 protein (258) 258
aged (255) 255
tumors (254) 254
dendritic cells (247) 247
b7-h1 antigen - antagonists & inhibitors (232) 232
activation (225) 225
cell line, tumor (223) 223
t-lymphocytes - immunology (215) 215
mice, inbred c57bl (208) 208
research (208) 208
flow cytometry (206) 206
lymphocytes t (200) 200
t-cells (196) 196
blockade (194) 194
programmed cell death 1 receptor - metabolism (194) 194
cd8-positive t-lymphocytes - immunology (190) 190
prognosis (190) 190
gene expression (176) 176
programmed cell death 1 receptor - immunology (175) 175
pd-1 protein (174) 174
melanoma (170) 170
b7 family (168) 168
health aspects (165) 165
multidisciplinary sciences (159) 159
abridged index medicus (158) 158
immunohistochemistry (158) 158
programmed cell death 1 receptor - antagonists & inhibitors (158) 158
antigens (157) 157
care and treatment (156) 156
cell biology (152) 152
hematology (151) 151
programmed cell death 1 receptor (149) 149
immune system (147) 147
research article (146) 146
up-regulation (146) 146
immunity (145) 145
immune response (136) 136
signal transduction (132) 132
metastasis (131) 131
patients (131) 131
medicine, research & experimental (130) 130
cytokines (128) 128
dendritic cells - immunology (127) 127
regulatory t-cells (127) 127
cell proliferation (126) 126
cells, cultured (126) 126
immune checkpoint (126) 126
medicine (124) 124
genetic aspects (120) 120
cancer therapies (119) 119
aged, 80 and over (115) 115
chemotherapy (113) 113
responses (113) 113
survival (113) 113
lung cancer (112) 112
medical prognosis (111) 111
nivolumab (111) 111
antigens, cd - metabolism (109) 109
mice, inbred balb c (108) 108
receptor (108) 108
neoplasms - immunology (107) 107
t cell receptors (107) 107
immunotherapy - methods (106) 106
biomarkers (104) 104
cell death (104) 104
inflammation (104) 104
t-lymphocytes - metabolism (104) 104
mice, knockout (103) 103
lymphocyte activation (100) 100
pathway (100) 100
proteins (100) 100
safety (100) 100
t-lymphocytes, regulatory - immunology (100) 100
analysis (99) 99
programmed death-1 (99) 99
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1512) 1512
Chinese (34) 34
French (2) 2
German (2) 2
Russian (2) 2
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature, ISSN 0028-0836, 08/2018, Volume 560, Issue 7718, pp. 382 - 386
Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1... 
CELLS | MELANOMA | PEMBROLIZUMAB | EXTRACELLULAR VESICLES | MULTIDISCIPLINARY SCIENCES | RESISTANCE | INDUCE APOPTOSIS | EXPRESSION | T-LYMPHOCYTES | NECK-CANCER | CHECKPOINT BLOCKADE | Exosomes - metabolism | Tumor Escape - drug effects | Prognosis | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Case-Control Studies | Neoplasm Metastasis | Immune Tolerance - immunology | Antibodies, Monoclonal, Humanized - pharmacology | Female | Immune Tolerance - drug effects | Tumor Escape - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - pathology | B7-H1 Antigen - immunology | Disease Progression | Antineoplastic Agents, Immunological - pharmacology | Xenograft Model Antitumor Assays | B7-H1 Antigen - metabolism | Animals | B7-H1 Antigen - blood | Antineoplastic Agents, Immunological - therapeutic use | Melanoma - immunology | Mice, Nude | CD8-Positive T-Lymphocytes - drug effects | Interferon-gamma - immunology | Melanoma - drug therapy | Cell Line, Tumor | Mice | Programmed Cell Death 1 Receptor - immunology | CD8-Positive T-Lymphocytes - immunology | Interferon-gamma - blood | Viral antibodies | Immunosuppression | Antibodies | Metastasis | Research | T cells | Properties | Biological response modifiers | Therapy | PD-1 protein | CD8 antigen | Lymphocytes T | Exosomes | Cancer therapies | Metastases | Skin cancer | Proteins | Vesicles | Lymphocytes | Immunotherapy | Immune system | Immunoglobulins | Melanoma | Immunosurveillance | T cell receptors | Patients | Immune checkpoint | Microscopy | PD-L1 protein | Ligands | Interferon | Head & neck cancer | Tumors | Apoptosis
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 67 - 76
Journal Article
Diabetes, ISSN 0012-1797, 08/2018, Volume 67, Issue 8, pp. 1471 - 1480
Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year... 
Neoplasms - metabolism | Autoimmune Diseases - physiopathology | Humans | Isoantibodies - analysis | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Diabetes Mellitus, Type 1 - etiology | Ketosis - prevention & control | Pancreatitis - immunology | HLA-DR4 Antigen - metabolism | Autoimmune Diseases - metabolism | Insulin Secretion | Pancreatitis - physiopathology | Hypoglycemic Agents - therapeutic use | Genetic Predisposition to Disease | Autoimmune Diseases - immunology | Diabetes Mellitus, Type 1 - genetics | Pancreas - drug effects | Programmed Cell Death 1 Receptor - metabolism | Genotype | Ketosis - etiology | Pancreas - metabolism | Pancreas - immunology | Pancreatitis - chemically induced | Diabetes Mellitus, Type 1 - drug therapy | Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | HLA-DR4 Antigen - genetics | Insulin - metabolism | Models, Immunological | Animals | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Agents, Immunological - therapeutic use | Diabetes Mellitus, Type 1 - blood | HLA-DR4 Antigen - blood | Pancreatitis - metabolism | Autoimmune Diseases - chemically induced | Insulin - therapeutic use | Civilian casualties | Complications and side effects | Usage | Cancer patients | Care and treatment | Type 1 diabetes | Analysis | Immunotherapy | Risk factors | Index Medicus | Abridged Index Medicus | 0501 | Symposium | Emerging Areas of Islet Biology | 2003
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2011, Volume 6, Issue 9, p. e23621
Journal Article
Leukemia, ISSN 0887-6924, 12/2014, Volume 28, Issue 12, pp. 2367 - 2375
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 13, pp. 3453 - 3460
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 07/2016, Volume 139, Issue 2, pp. 396 - 403
In our study, we demonstrate that ccRCC cell lines with impaired function of pVHL to degrade HIFα express elevated levels of PD‐L1. In vitro analysis provided... 
ccRCC | HIF | pVHL | PD‐L1 | PD-L1 | CANCER-CELLS | PATHWAYS | ANTIBODY | IDENTIFICATION | HIF1-ALPHA | ESCAPE | TUMOR-SUPPRESSOR PVHL | THERAPY | ONCOLOGY | MUTATIONS | BLOCKADE | Immunohistochemistry | Gene Expression | Kidney Neoplasms - genetics | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Humans | Gene Expression Regulation, Neoplastic | Gene Silencing | Carcinoma, Renal Cell - genetics | Kidney Neoplasms - metabolism | B7-H1 Antigen - genetics | Case-Control Studies | Carcinoma, Renal Cell - metabolism | B7-H1 Antigen - metabolism | B7-H1 Antigen - blood | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Cell Line, Tumor | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Mutation | Analysis | Cancer | Chemotherapy | Rodents | Kidney cancer | Hypoxia | Ligands | T cell receptors | Apoptosis | Drugs | Biotechnology | Hypoxia-inducible factor 1 | Correlation | Target recognition | PD-1 protein | Genes | Lymphocytes T | In vitro testing | Drug delivery | Inactivation | Immunosuppressive agents | Degradation | Inhibition | Hypoxia-inducible factors | Deactivation | Mortality | Immunosurveillance | Tumor cell lines | Patients | Surveillance | Cell death | PD-L1 protein | Reagents | VHL protein | Aberration | Neoplasia | Clear cell-type renal cell carcinoma | Tumors | Kidney transplantation
Journal Article